Early phase clinical studies of AR‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomas

OBJECTIVES: Two pilot studies of AR‐42, a pan‐histone deacetylase inhibitor, in human neurofibromatosis type 2 (NF2), vestibular schwannomas (VS), and meningiomas are presented. Primary endpoints included safety, and intra‐tumoral pharmacokinetics (PK) and pharmacodynamics (PD). METHODS: Pilot 1 is...

Descripción completa

Detalles Bibliográficos
Autores principales: Welling, D. Bradley, Collier, Katharine A., Burns, Sarah S., Oblinger, Janet L., Shu, Edina, Miles‐Markley, Beth A., Hofmeister, Craig C., Makary, Mina S., Slone, H. Wayne, Blakeley, Jaishri O., Mansouri, S. Alireza, Neff, Brian A., Jackler, Robert K., Mortazavi, Amir, Chang, Long‐Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Head and Neck, and Tumor Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513424/
https://www.ncbi.nlm.nih.gov/pubmed/34667843
http://dx.doi.org/10.1002/lio2.643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513424/
https://www.ncbi.nlm.nih.gov/pubmed/34667843
http://dx.doi.org/10.1002/lio2.643

Ejemplares similares